Global Iron Deficiency Anemia Drug Market Size By Type (Prescription Drugs, Over-the-Counter (OTC)), By Application (Child, Adult), By Region, And Segment Forecasts, 2023 to 2032

The Global Iron Deficiency Anemia Drug Market was valued at USD 3.4 billion in 2023 and is projected to reach USD 5.9 billion by 2031, growing at a CAGR of 7.1% during the forecast period (2023–2031). This growth is primarily driven by the rising global prevalence of iron deficiency anemia (IDA), especially among women and children, along with increasing public health initiatives aimed at eradicating micronutrient deficiencies. Additionally, the introduction of novel drug formulations with improved bioavailability and fewer gastrointestinal side effects is propelling market expansion.

Drivers:

1. Rising Prevalence of Iron Deficiency Anemia:

Iron deficiency is the most common nutritional disorder globally. According to WHO, over 30% of the global population suffers from anemia, mostly due to iron deficiency, creating a sustained demand for effective drug treatments.

2. Government and NGO Health Initiatives:

Numerous public health programs—particularly in developing regions—are boosting awareness, early diagnosis, and access to iron supplementation, which in turn supports the market.

3. Advancements in Drug Delivery Systems:

The development of intravenous (IV) iron therapies and liposomal iron supplements is addressing limitations of traditional oral formulations, driving the adoption of newer, more efficient drugs.

Restraints:

1. Side Effects of Oral Iron Supplements:

Traditional oral iron supplements can cause gastrointestinal disturbances, such as constipation, nausea, and abdominal pain, deterring patient adherence and limiting treatment outcomes.

2. Limited Accessibility in Low-Income Regions:

Despite efforts to increase healthcare access, availability of advanced iron therapies remains low in several underdeveloped areas due to economic and logistical challenges.

Opportunity:

1. Increasing Penetration in Emerging Markets:

Expanding healthcare infrastructure in countries like India, Brazil, and parts of Africa presents a lucrative opportunity for manufacturers to increase the reach of iron deficiency anemia drugs.

2. Growing Demand for Intravenous Iron Therapies:

IV formulations are increasingly preferred in cases where oral iron is ineffective or poorly tolerated, especially in chronic kidney disease (CKD) and inflammatory bowel disease (IBD) patients.

Market by System Type Insights:

By drug type, oral iron supplements dominated the market in 2023, accounting for the highest revenue share due to their low cost and widespread availability. However, the intravenous iron therapy segment is expected to witness the fastest growth during the forecast period. Products like ferric carboxymaltose and iron sucrose are gaining traction due to higher efficacy and better tolerability in severe or chronic cases.

Market by End-use Insights:

Based on end-use, hospitals emerged as the leading segment in 2023, driven by the high volume of anemia patients treated through institutional healthcare settings. The retail pharmacies segment is also significant, benefiting from the availability of OTC iron supplements and the growing trend of self-medication in non-severe cases.

Market by Regional Insights:

In 2023, Asia-Pacific held the largest market share, attributed to the high incidence of iron deficiency anemia, especially among women and children, coupled with strong governmental focus on nutrition programs. North America is projected to grow steadily, supported by increased adoption of IV iron therapies and better healthcare reimbursement frameworks. Meanwhile, Africa and Latin America offer untapped potential due to rising awareness and international health aid programs.

Competitive Scenario:

Key players operating in the global market include Abbott Laboratories, Pfizer Inc., Amgen Inc., Vifor Pharma, Sanofi S.A., Teva Pharmaceuticals, Zydus Lifesciences, Pharmacosmos, GlaxoSmithKline plc, and Akebia Therapeutics. These companies are actively engaged in R&D, mergers, and portfolio expansion. For instance:

In 2024, Vifor Pharma launched an enhanced IV iron formulation with improved bioavailability.

In 2023, Akebia Therapeutics expanded its global footprint by securing regulatory approvals for vadadustat in multiple Asian countries.

In 2022, Pfizer collaborated with public health organizations to supply low-cost iron supplements in sub-Saharan Africa.

Scope of Work – Global Iron Deficiency Anemia Drug Market

Key Market Developments:

March 2024: Sanofi announced the launch of a new liposomal iron supplement aimed at reducing GI side effects, targeting patients with mild-to-moderate anemia.

January 2024: Abbott Laboratories expanded its production capacity for ferrous sulfate tablets to meet rising demand in India and Southeast Asia.

October 2023: GlaxoSmithKline received FDA approval for a novel oral iron formulation designed for pediatric use with improved palatability.

FAQs:

What is the current market size of the Global Iron Deficiency Anemia Drug Market?

The market size was valued at USD 3.4 billion in 2023.

What is the major growth driver of the Global Iron Deficiency Anemia Drug Market?

The major driver is the rising global prevalence of iron deficiency anemia and increased public health awareness.

Which is the largest region during the forecast period in the Global Iron Deficiency Anemia Drug Market?

Asia-Pacific holds the largest regional share, driven by high incidence rates and government nutrition programs.

Which segment accounted for the largest market share in the Global Iron Deficiency Anemia Drug Market?

The oral iron supplement segment accounted for the largest market share in 2023.

Who are the key market players in the Global Iron Deficiency Anemia Drug Market?

Key players include Abbott Laboratories, Pfizer, Amgen, Sanofi, Teva Pharmaceuticals, and Vifor Pharma.